(Q46926438)

English

First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?

scientific article published in March 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16456811

First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16456811

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jorg Michels

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16456811

Trina Montemurro

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16456811

Nevin Murray

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16456811

Christian Kollmannsberger

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16456811

Kim Nguyen Chi

5

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16456811

language of work or name

0 references

publication date

1 March 2006

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16456811

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16456811

106

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16456811

5

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16456811

1041-1046

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16456811

Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21695

21 January 2018

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21695

7 January 2021

based on heuristic

inferred from DOI database lookup

The development of androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21695

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21695

7 January 2021

based on heuristic

inferred from DOI database lookup

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21695

7 January 2021

based on heuristic

inferred from DOI database lookup

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21695

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21695

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21695

7 January 2021

based on heuristic

inferred from DOI database lookup

Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21695

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21695

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21695

7 January 2021

based on heuristic

inferred from DOI database lookup

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21695

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21695

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21695

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21695

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21695

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21695

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16456811

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16456811

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46926438&oldid=1577698410"